In the current text, we specifically focus on two candidate routes: (i) disruption to the neuroendocrine systems, including disruptions to insulin, leptin, glucagon-like peptide-1 (GLP-1), and ghrelin; and (ii) systemic inflammation resulting from metabolic disease. The gene discussed is GCG; the disease is metabolic disease.